Science

Dipesh Uprety: TROPION-Lung05 – a phase II trial on NSCLC by Jacob Sands et al.

Dipesh Uprety and Jacob Sands

Jan 12, 2025, 13:43

Dipesh Uprety: TROPION-Lung05 – a phase II trial on NSCLC by Jacob Sands et al.

Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X about recent paper by Jacob Sands, Medical oncologist at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:

“TROPION-Lung05: a phase II trial.

Patients with advanced/metastatic NSCLC with actionable genomic alterations after disease progression on targeted therapy and chemotherapy received Dato-DXd.

ORR 35.8%, DCR 78.8%, Median DoR 7 months.”

“Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study”

Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Rachel Chiaverelli, Luis Paz-Ares, et al.

Dipesh Uprety: TROPION-Lung05 - a phase II trial on NSCLC by Jacob Sands et al.

More posts featuring Dipesh Uprety.

Aaron Lisberg cancer datopotamab deruxtecan Dipesh Uprety Jacob Sands Luis Paz-Ares Myung-Ju Ahn non-small cell lung carcinoma NSCLC OncoDaily Oncology Rachel Chiaverelli TROPION-Lung05 Study

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%